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CpRu-complexes containing water soluble phosphine PTA and 
natural purines adenine, guanine and theophylline: synthesis, 
characterization and antiproliferative properties 
Lazhar Hajji,[a] Cristobal Saraiba-Bello,[a] Gaspar Segovia-Torrente,[a] Franco Scalambra,[a] Antonio 
Romerosa*[a] 
 
Abstract: Complexes [RuCp(Adeninate–kN9)(PTA)2] (1), 
[RuCp(Guaninate–kN9)(PTA)2] (2), [RuCp(Theophyllinate–
kN7)(PTA)2] (3), [RuCp(Adeninate–kN9)(PPh3)(PTA)] (4), 
[RuCp(Guaninate–kN9)(PPh3)(PTA)] (5) and [RuCp(Theophyllinate–
kN7)(PPh3)(PTA)] (6) were synthesized and characterized by NMR 
spectroscopy, elemental analysis and FT-IR (PTA = 1,3,5-triaza-7-
phosphaadamantane). Crystal structures of 1·H2O·3EtOH, 
3·CH3COCH3 and 4·H2O were also determined by single crystal X-
ray diffraction. The antiproliferative activities of the complexes 
against cisplatin-sensitive T2 and cisplatin-resistant SKOV3 cell lines 
have also been evaluated. Theoretical studies were preformed to 
elucidate how the adeninate ligand is coordinated to the metal. 
Introduction 
After the discovery of the anticancer properties of cisplatin[1] in 
the sixties by Rosenberg, a huge number of metal derivatives 
have been synthesized and tested as therapeutic agents for 
cancer treatment.[2–10] Although the use of cisplatin and its 
analogues present important secondary effects,[11–17] they are 
still some of most widely used chemotherapeutic agents up to 
date.[18–22] To overcome the drawbacks associated to the 
platinum drugs, the research on metal complexes bearing 
different metals is a topic of primary interest.[23–29] Among the 
non-platinum cytotoxic complexes those containing ruthenium 
are the most promising.[28,30–36] The Ru(III) complexes NAMI-A[37–
40] and KP1019[41–43] entered in clinical trials and in 2011 Dyson 
et al. synthesised the first members of the RAPTA family,[39] 
which is constituted by Ru(II)-arene complexes containing water 
soluble phosphanes such as PTA (1,3,5-triaza-7-
phosphaadamantane) as hydrophile ligand. The members of this 
family showed to be particularly effective against platinum 
resistant cancer cells. The excellent antiproliferative activity 
showed by RAPTA complexes have deeply pushed their study 
[39,40,44–47] and have spread the use of PTA and its derivatives as 
ligands in cytotoxic metal complexes, which has been recently 
reviewed.[48–51] These type of ligands have been showed to be 
useful also to obtain Ru(II)-bipyridine[52] and Ru(II) piano-stool 
complexes with interesting antiproliferative profiles.  
The design of antiproliferative metal complexes requires, 
additionally to an active metal, the adequate combination of 
appropriate ligands that modulate both the activity and the 
partition coefficient of the complex. The latter has been found to 
be a factor of main importance to increase the cytotoxicity: the 
complex has to solubilize in both the water-rich plasma and the 
hydrophobic cell membrane.[53]  
Ligands PTA, mPTA (N-methyl-1,3,5-triaza-7-
phosphaadamantane) and its derivative dmoPTA (3,7-dimethyl-
1,3,7-triaza-5-phosphabicyclo[3.3.1] nonane) have an adequate 
hydrophilic/hydrophobic balance to move through the biological 
system, which most of the times does not vary after coordination 
to metals. We obtained promising results with platinum[54,55] and 
ruthenium[56] complexes containing the water soluble phosphine 
PTA and its derivative mPTA and noteworthy also with 
dmoPTA,[56–64] which showed to be an excellent ligand to 
synthesise ruthenium complexes active against cisplatin 
sensitive and resistant cell lines. 
It was showed that the binding of a ruthenium complex to 
natural purines could enhance the antiproliferative activity of 
both species by a synergic action and could affect the metal 
distribution in the cells by a ligand “carrier effect”. In the last 
years we also noticed that the introduction of a purine in the 
coordination sphere of piano-stool ruthenium complexes could 
enhance their antiproliferative activity. This was corroborated 
synthesising the ruthenium complexes [RuCp(X)(PTA)(L)] (X = 
8-thio-theophyllinate, 8-methylthio-theophyllinate, 8-benzylthio-
theophyllinate; L = PTA, PPh3) containing thiopurines. It was 
showed that the antiproliferative activity of these complexes 
against T2 (cisplatin-sensitive) and SKOV3 (cisplatin-resistant) 
cell lines was enhanced with respect to the starting 
compounds,[65] and to similar ruthenium complexes containing 
PTA or mPTA, but without the purine.[66] 
In this work we extend the study of the reactivity of 
[RuClCp(PTA)(L)] (L = PTA, PPh3) type complexes to the natural 
purines adenine, guanine and theophylline. The latter has been 
chosen due to the lack of the N10 coordination site, that 
simplifies its coordination chemistry, helping also the NMR 
characterization of the reaction products with adenine and 
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guanine by comparison. Interestingly the obtained results 
showed that adenine and guanine are coordinated by the 
imidazolic N9 atom, while theophylline by the N7. The resulting 
complexes [RuCp(X)(PTA)(L)] (X = kN9-adeninate, kN9-
guaninate, kN7-theophyllinate; L = PTA, PPh3) showed different 
partition coefficient and antiproliferative activity. A theoretical 
study on the ruthenium complexes with adeninate and guaninate 
was also performed with the aim to determine the reasons why 
purine is coordinated to the metal by the imidazolic N9 atom. 
Results and Discussion 
Reactivity of [RuClCp(PTA)2] with adenine, guanine and 
theophylline: synthesis and characterization of 1-3. 
Complex [RuClCp(PTA)2] was initially reacted with adenine, 
guanine or theophylline in water and in a mixture of water/EtOH 
at room and refluxing temperature. In these conditions no 
reaction occurred but when the purines were previously 
deprotonated the corresponding purinate substituted the chloride 
in the starting complex. The complexes 1-3 (adeninate for 1, 
guaninate for 2 and theophyllinate for 3) were obtained in good 
yield in refluxing EtOH/water by reaction of [RuClCp(PTA)2] with 
the resultant purinate of prepared by deprotonation of the purine 
with KOH in EtOH (Scheme 1). It is important to point out that all 
of the obtained compounds are stable in solid state for months 
under air at room temperature, and in water solution for more 
than 2 days, even when DMSO-d6 (from 10 to 50% v/v) was 
introduced in the solution and the temperature kept at 40 ºC. 
Also, complexes were stable for 1 day at room temperature and 
40 ºC in a DMSO- 
d6/cellular-culture dissolution. 
 
Scheme 1. Synthesis of 1-3. 
 
The 31P{1H} NMR of 1 showed a singlet at -23.17 ppm, that 
is similar to that observed for the starting complex 
[RuClCp(PTA)2] (-25.65 ppm) and corresponds to the PTA 
ligands.[67] The presence of the adeninate in 1 is evidenced by 
the characteristic IR strong absorption bands for d(NH2) (1629, 
1594 cm-1) and n(C=C+C=N) (1542 cm-1). The 1H NMR 
spectrum of 1 in D2O displays singlets at 7.66 ppm and 8.21 
ppm integrating 1 H, ascribable to adeninate-C2-H and C8-H 
respectively.[68–70] Unfortunately the complexes are not soluble 
enough in any aprotic solvent for observing the adeninate-NH2. 
The characteristic signals for Cp and PTA for a piano-stool 
structure were observed, supporting that the complex retains the 
same ligand configuration with respect to the starting complex. 
The Cp and PTA signals in the 13C{1H} NMR spectrum also 
agree with the proposed structure for 1, the rest of the spectrum 
does not deserve particular comments.  
Despite of the N7 imidazolic atom is the most popular 
coordination position for adenine with transition metals, at the 
best of our knowledge this is the first example characterized by 
single crystal X-ray diffraction of an adeninate-ruthenium 
complex mono-coordinated by N9.[71] Therefore, although in 1 
the most probable coordination of the adeninate to the 
ruthenium is the imidazolic N9, the spectroscopic evidences are 
not enough for ensuring this suspicion. Fortunately, crystals 
good enough for single crystal X-ray diffraction were obtained 
and the structure for 1 was fully determined (Figure 1). As 
expected the ruthenium is coordinated to a h5-Cp, to two PTA by 
the P atoms and to an adeninate by the N9. 
The elemental analysis, IR and NMR spectroscopy also 
supported that complex 2 is constituted by a ruthenium 
coordinated to a h5-Cp, two PPTA by the P atoms and a 
guaninate ligand, but newly these techniques do not provide 
evidences to propose which is the coordination site of the 
guaninate.[71] 
Complex 3 was fully characterized by spectroscopic 
techniques. Its IR spectrum, 1H and 13C{1H} NMR spectra 
showed that the theophylline is coordinated by the imidazolic N7 
atom, such as was observed in a large amount of similar Cp-
PTA-ruthenium examples containing thiotheophyllines, some of 
them fully characterized by single crystal X-ray diffraction.[58]  
 
Reactivity of [RuClCp(PPh3)(PTA)] against adenine, guanine 
and theophylline: synthesis and characterization of 
complexes 4-6 
Similarly to what described previously for the reactivity of 
[RuClCp(PTA)2], neither  the starting complex 
[RuClCp(PPh3)(PTA)] reacts with adenine, guanine and 
theophylline at room and refluxing temperature. Nevertheless, 
when purines were deprotonated, they substitute easily the 
chloride in the starting complex. The respective purinate was 
reacted with the starting complex [RuClCp(PPh3)(PTA)] 
(Scheme 2), affording quantitatively complexes 4-6 (4: 
adeninate; 5: guaninate; 6: theophyllinate). All of these 
complexes are not  
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soluble in water but in organic solvents such as CDCl3, in which  
they are stable for more than 2 days also when DMSO-d6 is 
added (from 10 to 50% v/v) at room temperature and at 40 ºC. In 
the solid state they are stable for months at room temperature 
under both N2 and air. 
The IR spectrum of complex 4 showed characteristic 
d(NH2) absorption bands (1623, 1593 cm-1) and n(C=C + C=N) 
(1541 cm-1) in the typical range found for an adeninate ligand 
coordinated to ruthenium.[68–70] This evidence was also 
supported by the 1H and 13C NMR spectra. In complex 4 the 
ruthenium is coordinated to four different ligands and therefore 
the metal is a chiral center (Scheme 2). The 1H NMR (CDCl3) 
displayed the expected sharp signals for one Cp, one PTA and 
one PPh3 ligand as well as signals for the NH2 (5.42 ppm), C2-H 
(7.71 ppm) and C8-H (8.34 ppm) of adeninate protons. The 
13C{1H} NMR of 4 presents the expected signals for its proposed 
composition. Interestingly, the 31P{1H} NMR spectrum showed 
the expected two doublets at 52.12 ppm (PPh3) and -35.74 ppm 
(PTA), somewhat shifted with respect to those of the starting 
complex [RuClCp(PPh3)(PTA)] (d PPh3 = 48.16 ppm; d PTA = -
34.96 ppm). These signals arise also at a different chemical shift 
to that found for the monometallic complexes containing 
thiopurinate ligands.[65] Again, looking at the spectroscopic data, 
it is not possible to guarantee which is the adeninate 
coordination site. The crystal structure of 4 was determined by 
single crystal X-ray diffraction (Figure 1) that shows how the 
ruthenium is coordinated with a piano-stool geometry to a h5-Cp, 
a PTA and a PPh3 by their P atoms and to the imidazolic N9 
atom of an adenine molecule.  
The complex 5 was synthesized by a procedure similar to 
that for 4 and therefore a similar complex was expected but 
containing guaninate instead of adeninate. The IR spectrum of 5 
showed the typical bands for coordinated guaninate 
(d(NH2)=1672 (s); n(C=O)=1608 (s); n(C=C+C=N)=1564 (m)),[72–
74] and its 1H NMR spectrum displays the characteristic signals 
for PPh3, PTA and Cp in a piano-stool configuration.[65] The 
guaninate signals arise at 5.86 ppm (NH2) and 7.14 ppm (C8-H), 
which are similar to those found for 2 (d(C8-H) = 7.35 ppm). In 
this complex the 13C{1H} NMR spectrum displays sharp peaks 
for Cp, PTA and PPh3 carbon atoms but broad signals for 
guaninate carbons, arising at chemical shifts (C5: 118.58 ppm; 
C8: 151.15 ppm; C4: 153.78 ppm; C2: 157.68 ppm; C6: 162.93 
ppm) similar to those found in 2 (C5: 116.60 ppm; C8: 151.37 
ppm; C4: 154.32 ppm; C2: 159.08 ppm; C6: 163.15 ppm). 
Therefore, it is reasonable that in both complexes the purinate is 
coordinated by the same coordination position. Finally, the 
31P{1H} NMR spectrum of 5 is constituted by two doublets with 
similar chemical shift and coupling constant with respect to 4.  
The IR absorption bands of 6 arise at similar frequency 
than those found in similar theophyllinate ruthenium 
complexes,[75–77] which suggests that purine is coordinated to the 
metal by the imidazolic N7 atom. The 1H NMR spectrum shows 
the signals expected for a metal coordinated to a h5-Cp, a PPh3, 
a PTA and the theophyllinate. The 1H NMR spectrum of complex 
6 displays broad signals. As indicated previously, the ruthenium 
atom is a chiral center and therefore different isomers can be 
obtained from the synthesis. The 1H, 13C{1H} and 31P{1H} NMR of 
6 are similar to complex [RuCp(thiopurinate)(PPh3)(PTA)] in 
which was also evident the presence of different isomers in 
solution.[56,65] Similarly to 4 and 5, the possible isomers 
constituting 6 were not isolated. 
 
Crystal structures of [RuCp(Adeninate–
kN9)(PTA)2]·H2O·3EtOH (1·H2O·3EtOH), 
[RuCp(Theophyllinate-kN7)(PTA)2]·(CH3COCH3) 
(3·CH3COCH3) and [RuCp(Adeninate–kN9)(PPh3)(PTA)]·H2O 
(4·H2O) 
Single crystals of (1·H2O·3EtOH) and (4·H2O) grew by slow 
evaporation of an ethanol/water solution containing the 
respective complex. The asymmetric units are constituted by a 
molecule of neutral complex [RuCp(Adeninate–kN9)(PTA)2] (1) 
or [RuCp(Adeninate-κN9)(PPh3)(PTA)] (4), plus crystallization 
solvent (water and/or ethanol). The complex units are typical 
piano stool h5-Cp moieties containing two PTA (1) or a PTA and 
a PPh3 (4). In both the cases the coordination sphere of the 
ruthenium is completed by an adeninate coordinated by its N9 
(Figure 1). At the best of our knowledge they represent the first 
example of monometallic Ru-adeninate complexes where the 
adeninate is coordinated to the ruthenium via N9 instead of the 
most accessible NH2. Up to date, the reported Ru-adenine 
complexes[68–70] are coordinated by N7/N9 (the polymetallic 
tetrakis((µ2-Adeninate-N7,N9)-(h6-benzene)-chloro-
ruthenium)tetrachloride-decahydrate)[78] and N7/NH2/N1 (Cyclo-
(tetrakis((µ2-Adeninate)-(h6-p-cymene)-ruthenium)tetrakis-
trifluoromethylsulfonate)[79,80] but there is not any 
crystallographycally characterized example in which an adenine 
molecule is mono-coordinated to a ruthenium atom through N9. 
 
 
Figure 1. Representations of the crystal structure of 1 and 4. For the sake of 
clarity the H atoms were omitted. 
 
 
The distances between the metal and the PTA or the PPh3, are 
in the expected range (1: Ru-P1 = 2.2834(9) Å, Ru-P2 = 
2.2556(6) Å; 4: Ru-P1 = 2.304(2) Å, Ru-P2 =  2.304(2) Å).[56,65] 
In complex 4 the Ru-P distances are identical, while in complex 
1 they are slightly different between each other, that was not 
observed in the starting complex [RuClCp(PTA)2] (Ru-P1 = 
2.258 Å, Ru-P2 = 2.247 Å). The Ru-Cpcentroid bond lengths are 
also similar to those of other similar piano-stool ruthenium 
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The Ru-N9 distances (1: 2.146(2) Å; 4: 2.142(7) Å) are 
comparable to those found in a polymetallic N7/N9-adeninate 
ruthenium complex (2.117(10) Å)[78] and in a N7/NH2/N9-
adeninate cyclo-ruthenium complex (Ru-N9 = 2.079(4) Å).[79,80]  
For what concern 1, the purine plane is located between both 
PTA molecules, while in 4 it is almost parallel to the Cp ring, 
probably to minimize the steric hindrance. The distances C8-N9 
(1: 1.363(4) Å; 4: 1.291(11) Å) and C8-N7 (1: 1.328(3) Å; 4: 
1.349(11) Å) indicate that the single bond character of C8-N9 
and the double bond character of C8-N7 bond are higher in 
complex 4 (1: D = 0.035(2) Å; 4: D= 0.058(11) Å). In both cases, 
the bond character is quite different than those found in N7-N9 
bridged Ru-adeninate complexes, such as complex [{RuCl(µ2-
adeninate-N7,N9)(h6-p-cymene)}4]4+ (N9-C8 = 1.329(4) Å; C8-N7 
= 1.335(4) Å; D = 0.006(4) Å).[78] This fact supports the single 
character for the bond between N9 and C8 while that between 
N7-C8 is close to double and agrees with complex trans-[Pd-
(adeninate)2(n-Bu3P)2],[81] in which the adeninate is bonded to 
the metal by only N9, the distances N9-C8 and C8-N7 (N9-C8 = 
1.359(5) Å; C8-N7 = 1.319(5) Å), are practically the same of 
those in 1 and 4, but also in Ni, Pt and Zn complexes containing 
the monodentate N9-coordinated-adeninate ligand.[82–84] The rest 
of the distances in the adeninate ligand in 1 and 4 are similar to 
those found in known Ru-adeninate complexes.[78–80] The angles 
around the ruthenium in 1 (P1-Ru-P2 = 96.01(3)º, P1-Ru-N9 = 
96.06(7)º, P2-Ru1-N9 = 88.17(7)º) and 4 (P1-Ru-P2 = 95.96(7), 
P1-Ru-N9 = 95.48(18)º, P2-Ru1-N9 = 90.75(19)º) are 
approximately 1 - 5º wider than those in the respective starting 
complexes, presumably due to the steric hindrance imposed by 
the adeninate. In the packing of both 1·H2O·3EtOH and 4·H2O, 
the complex units are dimerized through a network of hydrogen 
bonds involving the water or ethanol solvate and the non 
coordinated nitrogens of the adeninate ligand. 
For what concern 3·CH3COCH3, single crystal were obtained by 
evaporation of an acetone solution of 3. It is the first example of 
a ruthenium complex containing theophylline determined by 
single crystal X-ray diffraction, according to CCDC.[71] A 
representation of the complex structure is displayed in Figure 2, 
the crystallographic data are showed in Table 1 and a list of 
selected bond distances and angles in Table 2. The asymmetric 
unit contains one [RuCp(theophyllinate-kN7)(PTA)2] complex 
and one acetone molecule. The complex unit is constituted by a 
distorted piano-stool octahedral ruthenium coordinated to a h5-
Cp, two PTA via κP and a theophylline by the imidazolic N7 
atom. The Ru-P and Ru-N are similar to 1 and 4 and agree with 
what found for similar complexes (Ru-P1 = 2.271(1) Å, Ru-P2 = 
2.267(1) Å, Ru-N1 = 2.142(4) Å).[56,65][85] The purinate plane is 
almost parallel to the Cp ring, as observed in 4. The distances 
C8-N7 (1.339(6) Å) and C8-N9 (1.346(6) Å) are similar to each 
other, while the C5-N7 bond length is somewhat longer 
(1.409(6) Å), which agrees well with theophyllinate complexes of 
Cu,[86] Au,[70] Cd,[87] Hg,[88,89] Co[90] and Zn.[91] The angle between 
PTA ligands (P1-Ru-P2 = 93.06(4)º) is shorter than in 1 and 4, 
and it is nearly bisected by the Ru-N7 bond (P1-Ru-N7 = 
93.37(10)º, P2-Ru-N9 = 93.37(10)º). 
 
 
Figure 2. Representation of the crystal structure of 3. 
Table 2. Selected bond lengths and angles for 1, 3 and 4. 
 1 3 4 
 Bond length (Ǻ) 
Ru1-P1 2.2834(9) 2.271(1) 2.304(2) 
Ru1-P2 2.2556(6) 2.267(1) 2.304(2) 
Ru1-N7 - 2.142(4) - 
Ru1-N9 2.146(2) - 2.142(7) 
N7-C5 1.372(4) 1.409(6) 1.389(11) 
N7-C8 1.328(3) 1.339(6) 1.349(11) 
N9-C4 1.364(3) 1.354(6) 1.388(9) 
N9-C8 1.363(4) 1.346(6) 1.291(11 
C4-C5 1.394(4) 1.377(6) 1.406(11) 
 Angle (º) 
P1-Ru1-P2 96.01(3) 93.06(4) 95.95(7) 
P1-Ru1-N7 - 93.37(10) - 
P1-Ru1-N9 96.06(7) - 95.48(18) 
P2-Ru1-N7 - 93.35(10) - 
P2-Ru1-N9 88.17(7) - 90.75(19) 
 
Theoretical calculations 
In order to shed light on why Ru is coordinated to the imidazolic 
N9 atom instead of the N7, bond energies and bond orders were 
calculated for complexes 1, 4 and their N7-coordinated 
analogues 1a, 4a and 4b (Figure S21). For complexes 1 and 4 
the calculated Ru-N9 bond length was similar to that in crystal 
structure (differences < 1%).  
Complex 1 is 12.8 kcal/mol more stable than its N7 isomer 
1a (Figure S21). For what concern 4, two different disposition of 
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pointing to the PTA (4a) or to the PPh3 (4b). These complexes 
showed to be even less stable than 4 but also than 1b (4-4a: 
14.2 kcal/mol; 4-4b: 15.5 kcal/mol). The dissociation energy of 
the {RuCp(L2)}+ moiety from the adeninate ligand is higher if the 
ligand is coordinated by the imidazolic N7 atom (1-1a: 13.2 
Kcal/mol; 4-4a: 23.2 kcal/mol; 4-4b: 24.5 kcal/mol), therefore 
these results support that the Ru-N9 bond is stronger that the 
Ru-N7. These results evidence not only that 1 and 4 are more 
stable than 1a and 4a/b, respectively, but also that the energy 
gap between Ru-N7 and Ru-N9 isomers increases when a PTA 
is replaced with a bulkier triphenylphosphine. This suggests that 
the adeninate-N7 coordination could be less favored than the N9 
due to the steric hindrance imposed by the adeninate-NH2 group 
and the bulky PPh3.  
 
Cell Growth Inhibition 
There are significant examples on how the antiproliferative 
activity of metal complexes is amplified when they are reacted 
with biologically active molecules and in particular with natural 
purines. With this idea in mind, the cell growth inhibition 
activities of complexes 1-6 were evaluated. 
Complexes 1-3 and 4-6 have been tested for cell growth 
inhibition activity on the cisplatin-sensitive human cancer cell 
lines T2 and on the cisplatin-resistant SKOV3 and compared 
with the starting complexes [RuClCp(PTA)2] and 
[RuClCp(PPh3)(PTA)] (results reported in Table 3). Despite of 
the growth inhibition activity for cisplatin and starting compounds 
were previously published,[56] they were also checked in the 
same experiment for the sake of comparison. The general 
standard procedure consist in dissolving the complex in DMSO 
and quick addition of AIM-V medium to obtain solutions of 50, 10 
and 2 µM. The percentage of growth inhibition at the three doses 
for each complex allowed us to estimate the IC50, the 
concentration reducing to 50% the cell growth of both cell lines. 
Complexes 1-6 are stable under air in solid state for months and 
in water and in a mixture of water/DMSO under air at both room 
temperature and 40 ºC for 2 days. 
Tests with the cisplatin-sensitive cells T2 showed that 
complex 4 displays a significantly better activity than the others. 
The antiproliferative activities of related PTA Ru[56,65] and Pt[55] 
complexes were correlated with their solubility in lipophilic media, 
which is connected with the ability of the compound to cross the 
lipophilic membranes of the cell. If the antiproliferative action 
mechanism involves the reaction of the compound with internal 
components of the cell, only those complexes capable of 
crossing membranes can react with internal cell components. 
Partition coefficients, Log P, for complexes (Table 3) show as 
the complexes 4-6, containing PTA and PPh3, are more lipophilic 
(positive Log P) than 1-3, which bear two PTA. Nevertheless, 
despite complex 4 shows both the largest antiproliferative 
activity and Log P, supporting the initial idea than the 
antiproliferative activity is related with the partition coefficient, 
complex 5, which displays the second larger partition coefficient, 
does not show significant antiproliferative activity.  
For the sake of looking for some other parameters that 
could determine the observed antiproliferative activity, the water 
solubility and the oxidation potential of the complexes were 
taken in account (Table 3). More data are needed to ensure a 
tendency but from the results obtained complex 4, which show 
the largest antiproliferative activity, also display the largest water 
solubility and oxidation potential. Complex 4 displays the highest 
activity against T2 cell line, better than that for cisplatin. Tests 
with the cisplatin-resistant SKOV3 cell line showed that this 
complex is also more active than cisplatin on Pt-resistant cell 
line. This observation supports the hypothesis that complex 4, 
which is as active as cisplatin on Pt-sensitive cells and also 
more active than cisplatin on Pt resistant cell line, could act by a 
different mechanism than the classical Pt containing drugs. 
Despite of all of the available Ru coordination sites are filled, the 
ligands could be substituted by a nucleophile inside the cell such 
as a DNA-purine, similarly to Cl in cisplatin is substituted first by 
H2O and finally for DNA-guanine. Nevertheless, and taking in 
account the observed stability of the complexes in DMSO-d6 and 
DMSO-d6/cell-culture-medium, an alternative to this hypothesis 
could be formation of the strong hydrogen bonds between DNA 
purine bases and the adenine in 4 as it was observed between 
adenines of neighbors molecules in the crystal structure. 
Although this possibility is intriguing, a large and intense 
research work needs to be done to determine if this effect could 




Table 3. Estimated IC50 on cisplatin sensitive T2 cell line and cisplatin-resistant 
SKOV3 of complexes 1-6, Log P, S25,H2O and Eo. 
Complex 
IC50 (µM) 




[RuClCp(PTA)2] > 50 > 50 -1.85   
1 >50 > 50 -0.82 15.8 0.620 
2 > 50 > 50 -1.19 3.5 0.974 
3 >50 > 50 -0.45 14 0.684 
[RuClCp(PPh3)(PTA)] 10-50 > 50 0.75   
4 <2 30±20 1.4 0.6 0.690 
5 >50 > 50 1.32 0.4 0.407 
6 ca 50 ca 50 0.81 0.8 0.726 
cisplatin 6±4 > 50    
 
Conclusions 
The reactivity of starting complexes with antiproliferative activity 
[RuClCp(PTA)2] and [RuClCp(PPh3)(PTA)] against natural 
purines adenine, guanine and theophylline showed that reaction 
proceed when purine is previously deprotonated. The six new 
Ru(II) complexes obtained display a similar structure constituted 
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phosphines by the P atoms and the natural purinate (1-3: 
containing two PTA; 4-6: containing a PTA and a PPh3). The 
antiproliferative activities of complexes 1-6 were evaluated on 
model tumoral cell lines T2 and SKOV3. Only complex 4 
([RuCp(Adeninate–kN7)(PPh3)(PTA)]), showed similar activity to 
cisplatin on T2 cell line but better than cisplatin on SKOV3 cell 
line. The valuable anticancer activity of 4 is probably due to a 
convenient hydrophilicity/lipophilicity balance reached upon 
combination of the ligands, associating one hydrophilic PTA with 
the lipophilic PPh3 and the adenine, but also its oxidation 
potential could have some substantial influence.  
It is captivating to consider that the real reason that can 
justify the antiproliferative activity of 4 is its capability of forming 
strong hydrogen bonds through the adenine-atoms with the 
DNA-purine bases, making the interaction mechanism different 
than that for starting complex. A large work is needed to support 
this idea, but for sure, the piano-stool ruthenium complexes 
could improve its antiproliferative activity including in its 
composition natural purine. 
Experimental Section 
General Procedures. All chemicals were reagent grade and were used 
as received by commercial suppliers unless otherwise stated. The 
solvents were all degassed and distilled according to standard 
procedures.[92] All reactions and manipulations were routinely performed 
under a dry nitrogen atmosphere by using standard Schlenk-tube 
techniques. The compounds PTA, [RuClCp(PTA)2] and 
[RuClCp(PPh3)(PTA)] were prepared as described in the literature.[56,67,93] 
Solvents for NMR measurements (Cortec-Euriso-top) was dried over 
molecular sieves (0.4 nm). 1H, 31P{1H} NMR and 13C{1H} NMR spectra 
were recorded on a Bruker DRX300 spectrometer operating at 300.13 
MHz (1H), 121.49 MHz (31P) and 75.47 MHz (13C), respectively. Peak 
positions are relative to tetramethylsilane and were calibrated against the 
residual solvent resonance (1H) or the deuterated solvent multiplet (13C). 
Chemical shifts for 31P{1H} NMR were measured relative to external 85 % 
H3PO4 with downfield values taken as positive. Infrared spectra were 
recorded on KBr discs using an FT-IR ATI Mattson Infinity Series. 
Elemental analysis (C, H, N, S) was performed on a Fisons Instruments 
EA 1108 elemental analyser. 
 
Synthesis of [RuCp(Adeninate–kN9)(PTA)2] (1), [RuCp(Guaninate–
kN9)(PTA)2] (2) and [RuCp(Theophyllinate–kN7)(PTA)2] (3). The 
complexes containing two PTA ligands were obtained through the same 
procedure by reacting the purinate, previously obtained by reaction 
between the purine and KOH, and the starting complex [RuClCp(PTA)2] 
in a mixture of EtOH/H2O. The purine (1, Adenine: 18.53 mg, 0.14 mmol; 
2, Guanine: 24.22 mg, 0.16 mmol; 3, Theophylline: 27 mg, 0.15 mmol) 
and KOH (1, 2, 3: 7.74 mg, 0.14 mmol) were reacted initially in 10 mL of 
EtOH. After 15 minutes 20 mL of H2O were added into the resulting 
mixture giving rise to a colourless dissolution. After 15 minutes at room 
temperature the ruthenium complex [RuClCp(PTA)2]) (1, 2, 3: 70.87 mg, 
0.14 mmol) was added. The resulting dissolution was kept at refluxing 
temperature for 4 h, cooled at room temperature, filtered through sintered 
glass, and the solvent was removed. The resulting oil was dissolved in 2 
mL of EtOH, the dissolution filtered through a sintered glass and 10 mL 
of Et2O were added. The precipitated yellow powder was filtered, washed 
with Et2O (2 x 2 mL) and vacuum dried. 
 
1: Crystals useful for single crystal X-ray determination were obtained by 
slow recrystallization from an EtOH solution of the yellow powder 
obtained. Yield powder: 54.28 mg, 65 %. S25,H2O(mg/cm3): 15.8. Log P: -
0.82. Elemental analysis for C22H33N11RuP2 (614,59): Found C, 42.77; H, 
5.63; N, 24.87 %; calcd. C 42.99; H 5.41; N 25.07 %. IR (KBr, cm-1): 
d(NH2) 1629, 1594 (s); n(C=C+C=N) 1542 (s). 1H RMN (293 K, D2O): d 
3.89-4.9 (m, CH2PPTA, 12H); 4.49-4.87 (m, CH2NPTA, 12H); 4.82 (s, Cp, 
5H); 7.66 (s, C2-HAd, 1H); 8.21 (s, C8-HAd, 1H). 13C{1H} RMN (293 K, 
D2O): d 55.40 (t, 1JCP = 8.09 Hz, NCH2PPTA); 70.59 (bs, NCH2NPTA); 78.15 
(s, Cp); 119.62 (s, C5Ad); 149.85 (s, C8Ad); 154.07 (bs, C4Ad); 156.54 (s, 
C2Ad); 160.80 (s, C6Ad). 31P{1H} RMN (293 K, D2O): d -23.17 (s, PTA). E 
= 508 mV; DEp = 112 mV. 
 
2: Yield powder: 123.83 mg, 71 %. S25,H2O(mg/cm3): 3.5. Log P: -1.19. 
Elemental analysis for C22H33N11RuP2O (630.59): Found C, 41.77; H 
5.43; N 24.11 %; calcd. 41.91; H 5.27; N 24.43 %. IR (KBr, cm-1): d(NH2) 
1670 (s); n(C=O) 1625 (s); n(C=C+C=N) 1546 (m). 1H RMN (293 K, 
D2O): d 3.91-4.06 (m, CH2NPTA, 12H); 4.41-4.83 (m, CH2PPTA, 12H); 4.75 
(s, Cp, 5H); 7.35 (s, C8-HGu, 1H). 13C{1H} RMN (293 K, D2O): d 55.23 (t, 
1JCP = 7.93 Hz, NCH2PPTA); 70.63 (s, NCH2NPTA); 78.41 (s, Cp); 116.60 (s, 
C5Gu); 151.37 (s, C8Gu); 154.32 (s, C4Gu); 159.08 (s, C2Gu); 163.15 (s, 
C6Gu). 31P{1H} RMN (293 K, D2O): d -22.78 (s, PTA). E = 768 mV; DEp = 
106 mV. 
 
3: Twinned crystals were obtained by slow recrystallization from a water 
solution of the yellow powder. Yield powder: 171.61 mg, 82 %. 
S25,H2O(mg/cm3): 14. Log P: -0.45. Elemental analysis for 
C24H36N10O2P2Ru (659.63): Found C, 43.78; H 5.62; N 21.15 %; calcd. C 
43.70; H 5.50; N 21.23 %. IR (KBr, cm-1): n(C6=O) 1676 (s); n(C2=O) 
1639 (s); n(C=C+C=N) 1527 (m). 1H RMN (293 K, D2O): d 3.23 (s, 
CH3N1Tf, 3H); 3.31 (s, CH3N3Tf, 3H); 4.10-4.95 (m, CH2PPTA, 12H); 4.93 
(s, Cp, 5H); 7.16 (s, C8-HTf, 1H). 13C{1H} RMN (293 K, D2O): d 28.27 (s, 
CH3N1Tf); 29.84 (s, CH3N3Tf); 54.54 (bs, NCH2PPTA); 70.64 (bs, 
NCH2NPTA); 78.76 (s, Cp); 116.80 (s, C5Tf); 150.10 (s, C8Tf); 152.60 (s, 
C4Tf); 154.13 (s, C2Tf); 157.48 (s, C6Tf). 31P{1H} RMN (293 K, D2O): d -
24.21 (s, PTA). E = 590 mV; DEp = 94 mV. 
 
Synthesis of [RuCp(Adeninate–kN7)(PPh3)(PTA)] (4), 
[RuCp(Guaninate–kN7)(PPh3)(PTA)] (5) and [RuCp(Theophyllinate–
kN7)(PPh3)(PTA)] (6). Complexes 5, 6 and 7 were synthesized by a 
procedure similar to that described previously for complexes 1, 2 and 3, 
but using only EtOH as solvent. Into a 20 mL vessel was introduced the 
purine (5, Adenine: 21.00 mg, 0.15 mmol; 6, Guanine: 25.30 mg, 0.17 
mmol; 7, Theophylline: 32 mg, 0.16 mmol), KOH (5, 6, 7: 8,00 mg, 0.14 
mmol) and 10 mL of EtOH. The mixture was stirred at room temperature 
for 15 minutes and then complex [RuClCp(PPh3)(PTA)]) (5, 6, 7: 80.40 
mg, 0.13 mmol) was added. The mixture was refluxed for 4 h, cooled, 
filtered through sintered glass and concentrated to 2 mL. A yellow 
precipitate was obtained by addition of 5 mL of Et2O, which was filtered, 
washed with Et2O (2 x 2 mL) and vacuum dried.  
 
4: Single crystals were obtained by slow recrystallization from an EtOH 
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crystals: 53.41 g, 53 %. S25,H2O(mg/cm3): 0.6. Log P: 1.4. Elemental 
analysis for C34H36N8P2Ru (719.72): Found C, 56.82; H, 5.11; N, 
15.13 %; calcd. C, 56.74; H, 5.04; N, 15.57 %. IR (KBr, cm-1): d(NH2) 
1623, 1593 (s); n(C=C+C=N), 1541 (s). 1H RMN (293 K, CDCl3): d 3.46-
3.98 (m, CH2PPTA, 6H); 4.17-4.41 (m, CH2NPTA, 6H); 4.60 (s, Cp, 5H); 
5.42 (bs, NH2Ad, 2H); 7.20-7.56 (m, aromatic, 15H); 7.71 (s, C2-HAd, 1H); 
8.34 (s, C8-HAd, 1H). 13C{1H} RMN (293 K, CDCl3): d 56.37 (d, 1JCP = 
13.18 Hz, NCH2PPTA); 72.87 (d, 1JCP = 5.65 Hz, NCH2NPTA); 79.87 (s, 
Cp); 120.80 (s, C5Adn); 128.44-133.52 (m, aromatic); 138.20 (s, C8Ad); 
149.91 (s, C4Ad); 154.14 (s, C2Ad); 161.86 (s, C6Ad). 31P{1H} RMN (293 K, 
CDCl3): d -35.74 (d, 2JPP = 41.16 Hz, PTA); 52.12 (d, 2JPP = 41.16 Hz, 
PPh3). Eox1: 690 mV; Eox2 = 916 mV.  
 
5: Yield powder: 87.40 mg, 83 %. S25,H2O(mg/cm3): 0.4. Log P: 1.32. 
Elemental analysis for C34H36N8P2Ru (735.75): Found C, 55.60; H 5.02; 
N 15.09 %; calcd. C, 55.51; H 4.93; N 15.23 %. IR (KBr, cm-1): d(NH2) 
1672 (s); n(C=O) 1608 (s); n(C=C+C=N) 1564 (m). 1H RMN (293 K, 
DMSO-d6): d 3.53-3.96 (m, CH2PPTA, 6H); 4.00-4.43 (m, CH2NPTA, 6H); 
4.66 (s, Cp, 5H); 5.86 (bs, NH2Gu, 2H); 7.14 (s, C8-HGu, 1H); 7.20-7.65 (m, 
aromatic, 15H). 13C{1H} RMN (293 K, DMSO-d6): d 55.10 (d, 1JCP = 15.23 
Hz, NCH2PPTA); 72.56 (d, 1JCP = 5.70 Hz, NCH2NPTA); 80.32 (s, Cp); 
118.58 (s, C5Gu); 128.71-133.78 (m, aromatic); 151.15 (s, C8Gu); 153.78 
(s, C4Gu); 157.68 (s, C2Gu); 162.93 (s, C6Gu). 31P{1H} RMN (293 K, 
DMSO-d6): d -39.86 (d, 2JPP = 40.70 Hz, PTA); 53.83 (d, 2JPP = 40.70 Hz, 
PPh3). E = 339 mV; DEp = 68 mV. 
 
6: Yield powder: 89.92 mg, 73 %. S25,H2O(mg/cm3): 0.8. Log P: 0.81. 
Elemental analysis for C36H39N7O2P2Ru (764.76): Found C, 56.62; H 
5.20; N 12.65 %; calcd. C, 56.54; H 5.14; N 12.82 %. IR (KBr, cm-1): 
n(C6=O) 1681 (s); n(C2=O) 1628 (s); n(C=C+C=N) 1526 (m). 1H RMN 
(293 K, CDCl3): d 3.44-3.75 (m, CH2NPTA, 6H); 3.46 (bs, CH3N1Tf, 3H); 
3.66 (bs, CH3N3Tf, 3H); 4.10-4.49 (m, CH2PPTA, 6H); 4.41 (s, Cp, 5H); 
7.28-7.74 (m, aromatic, 15H). 13C{1H} RMN (293 K, CDCl3): d 28.17 (bs, 
CH3N1Tf); 29.77 (bs, CH3N3Tf); 55.08 (d, 1JCP = 12.51 Hz, NCH2PPTA); 
72.83 (d, 1JCP = 5.84 Hz, NCH2NPTA); 80.40 (s, Cp); 117.14 (bs, C5Tf); 
127.90-133.94 (m, aromatic); 148.56 (bs, C8Tf); 152.04 (bs, C4Tf); 154.73 
(bs, C2Tf); 157.41 (bs, C6Tf). 31P{1H} RMN (293 K, CDCl3): d -37.74 (d, 
2JPP = 43.46 Hz, PTA); 52.36 (d, 2JPP = 43.46 Hz, PPh3). Eox = 726 mV. 
 
Single crystal X-Ray diffraction. Data of compounds [RuCp(Adenine–
kN9)(PTA)2] (1), [RuCp(Theophyllinate–kN7)(PTA)2] (3) and 
[RuCp(Adenine–kN7)(PPh3)(PTA)] (4) were collected on a Bruker APEX 
CCD diffractometer (XDIFRACT service of the University of Almería) 
using graphite monochromated Mo Ka radiation (l = 0.7107 Å) at 150 K. 
The crystal parameters and other experimental details of the data 
collections for complexes 1, 3 and 4 are summarized in Table 1. Using 
the Olex2 software suite,[94] the structures were solved with the ShelXT[95] 
structure solution program using Intrinsic Phasing and refined with the 
ShelXL[96] refinement package using Least Squares minimisation. The 
data of 3 were integrated as a two components twin using SAINT. The 
exact twin matrix identified by the integration program was found to be -
1.00007 -0.00002 0.00047, -0.87269 1.00008 -0.18402, -0.00116 
0.00096 -1.00001. The absorption was corrected using Twinabs.[97] The 
structure was refined using the hklf 5 procedure, resulting in a BASF 
value of 0.5429(12). The structures have been deposited at the 
Cambridge Crystollagraphic Data Centre and the following deposition 
numbers were assigned: CCDC 1913360 (1), CCDC 1913362 (3) and 
CCDC 1913364 (4). 
Growth Inhibition Assays. Cell growth inhibition assays were carried 
out by using the cisplatin-sensitive T2 human cell line and the cisplatin-
resistant SKOV3 cell line for the sake of comparison with the starting 
complexes [RuClCp(PTA)2] and [RuClCp(PPh3)(PTA)].[55] T2 is a cell 
hybrid obtained by the fusion of the human lynphoblastoid line 174 (B 
lymphocyte transformed by the Epstein-Barr virus) with the CEM human 
cancer line (leukaemia T) while SKOV3 is derived from a human ovarian 
tumour. The cells were seeded in triplicate in 96-well trays at a density of 
50·103 in 50 µl of AIM-V medium for T2, 25·103 in 50 µl of AIM-V medium 
for SKOV3. Stock solutions (10 mM) of the ruthenium complexes 1-6 
were made in DMSO and diluted in AIM-V medium to give final 
concentration of 2, 10 and 50 µM. Cisplatin was employed as a control 
for the cisplatin-sensitive T2 cell line and for the cisplatin-resistant 
SKOV3. Untreated cells were placed in every plate as a negative control. 
The cells were exposed to the compounds for 72 h and then 25 µl of a 
4,5-dimethylthiozol-2-yl)2,5-diphenyltetrazolium bromide solution (12 
mM) were added. After two hours of incubation, 100 µl of lysing buffer 
(50% DMF + 20% SDS, pH 4.7) were added to convert 4,5-
dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide into a brown 
coloured formazane. After additional 18 hours the solution absorbance, 
proportional to the number of live cells, was measured by 
spectrophotometer and converted in % of growth inhibition.[98] 
 
Stability Tests of the Complexes with O2 and H2O. The obtained 
ruthenium complexes were air stable for months in the solid state and for 
2 days in solution. In a standard procedure, 0.01 g of 1, 2 and 3 were 
introduced into a 5 mm NMR tube and dissolved in 0.5 mL of D2O. The 
resulting solution was cooled to 5 °C and then dry O2 was bubbled 
throughout the solution for 2 min via a long syringe needle. 31P{1H} NMR 
showed that no significant changes were produced in 2 days at room 
temperature. No decomposition was also observed after 2 days at 40 °C 
as well. Additions of 50 μL of DMSO-d6 into the complex solutions did not 
produce any significant change in the starting complexes after 2 days at 
40 °C. A similar experiment was performed with 4, 5 and 6 but in CDCl3. 
These complexes showed to be stable in solution in both room 
temperature and 40 ºC for 2 days. Also, for these complexes additions of 
50 μL of DMSO-d6 into the solutions did not produce any significant 
change in the starting complexes after 2 days at 40 °C.  
Stability of 2·OTf·0.25H2O first with DMSO-d6 and immediately with 
cell culture medium. 5 mm NMR tubes were dissolved complexes (ca. 
5.4 mg) in 0,5 mL of DMSO-d6 and then added 0.6 mL of the used cell 
culture medium under air. Dissolutions were studied 31P{1H} NMR along 
the time at room temperature. For all the studied complexes the results 
were similar, no significant changes were observed after 1 day. Similar 
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Cyclic voltammetry experiments. Electrochemical experiments were 
performed with a VersaSTAT3 apparatus. A standard disposition for the 
measurement cell was used including a three-electrode glass cell 
consisting of a platinum disk working electrode, a platinum-wire auxiliary 
electrode and an Ag-metal reference electrode calibrate previously with 
ferrocene. The supporting electrolyte solution (LiClO4, 0.05 M) was 
scanned over the solvent window to verify the absence of electro-active 
impurities. A similar concentration of the analyte (0.1 mM) in DMF was 
employed in all the measurements. 
 
Octanol-Water Partition Coefficient Determination. The octanol-water 
partition coefficient of the ruthenium complexes was obtained by a slow-
stirring method that provides accurate Log P results over a wide range of 
concentration values.[99–101] The procedure was adapted to the solubility 
properties of the complexes. Solutions of the complexes in the range 
between 10-4 and 10-3 M were prepared in octanol previously saturated 
with distilled water. Into a 40 mL container with a magnetic stir bar was 
introduced initially 10 mL of the water phase previously saturated with 
octanol and then by a syringe 10 mL of the octanol one so that the 
solution did not emulsify. The container was closed with a silicone 
septum and stirred slowly at 25±1 ºC. Samples were taken from the 
octanol and water phases with a syringe through the septum. Samples 
of each phase were taken periodically until the concentrations in both 
phases stabilized. Concentrations of the complex in each phase were 
measured using UV-vis spectroscopy. 
 
Theoretical Methods. Geometry optimizations of 1, 1a, 4 and 4a were 
run using the NWChem6.3 program package.[102] Density-functional 
theory (DFT) were employed at the B3LYP/def2-SVP level of theory.[103–
105] For the ruthenium atom the effective core potential def2-ecp was 
applied. Bond energy corresponding to Ru-N7 (1, 4) or Ru-N9 (1a, 4a) 
have been obtained by subtracting the energy of the complex to the sum 
of the energies of the {RuCp(L)2}+ (L = PTA, PPh3) and (Adeninate)- 
moieties, considering heterolytic cleavage of the Ru-N bond. 
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Table 1. Crystallographic data for 1, 3 and 4. 
 1  3  4 
Empirical formula  C28H53N11O4P2Ru  C27H42N10O3P2Ru  C34H38N8OP2Ru  
Formula weight  770.82  717.71  737.73  
Temperature [K]  150  150  150  
Crystal system  triclinic  triclinic  monoclinic  
Space group  P-1  P-1  P21/c  
a [Å] 11.9945(10)  10.2996(11)  9.9148(17)  
b [Å] 12.0118(10)  12.2288(12)  18.386(3)  
c [Å]  13.5316(11)  12.9905(14)  17.514(3)  
α [°] 110.2820(10)  81.705(2)  90  
β [°] 93.2830(10)  82.803(2)  91.210(2)  
γ [°]  110.4200(10)  67.685(2)  90  
Volume [Å3] 1678.2(2)  1493.4(3)  3192.1(9)  
Z  2  2  4  
ρcalc [g/cm3] 1.525  1.596  1.535  
Μ [mm-1] 0.615  0.682  0.635  
F(000)  808.0  744.0  1520.0  
Crystal size [mm3] 0.06×0.04×0.02  0.5×0.3×0.2  0.04×0.03×0.02  
Radiation  MoKα  (λ = 0.71073)  
MoKα 
 (λ = 0.71073)  
MoKα  
(λ = 0.71073)  
Index ranges  
-13 ≤ h ≤ 15 
-15 ≤ k ≤ 10 
-16 ≤ l ≤ 17  
-12 ≤ h ≤ 13 
-15 ≤ k ≤ 15 
0 ≤ l ≤ 16  
-12 ≤ h ≤ 12 
-23 ≤ k ≤ 19 
-20 ≤ l ≤ 22  
Reflections 
collected  10304  6508  14957  
Data/restraints/ 
parameters  6916/2/437  6508/0/393  6676/5/431  
Goodness-of-fit  1.076  1.066  1.147  
Final R indexes 
[I>=2σ (I)]  
R1 = 0.0350 
wR2 = 0.0980  
R1 = 0.0487 
wR2 = 0.1160  
R1 = 0.0942 
wR2 = 0.1698  
Final R indexes [all 
data]  
R1 = 0.0378 
wR2 = 0.1001  
R1 = 0.0595 
wR2 = 0.1240  
R1 = 0.1281 
wR2 = 0.1888  
Largest diff. 
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